Key facts
- Lophora’s last known valuation is $19.5M (Jan 2025).
- It has raised $5.6M; the latest was Later Stage VC ($2.9M) in Jan 2025.
- Notable investors include BioInnovation Institute, BNC Korea, Innovationsfonden, Mystic Ventures, Novo Nordisk — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Lophora
- ·The full record, as it builds
Funding rounds
No funding rounds for Lophora are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lophora
Developer of neuroactive therapeutics designed to treat neurological and psychiatric disorders. The company offers clinical-stage central nervous system drug discovery programs and next-generation neuroactive compounds, enabling patients with depressive, anxiety, eating, mood, post-traumatic stress, and substance use disorders to access targeted treatment options under clinical development.
- Sector
- Healthcare
- HQ
- Charlottenlund, Denmark
- Founded
- 2018
- Employees
- 14
- Website
- lophora.com/
- Ownership
- Privately Held (backing)
Lophora doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lophora shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lophora in its N-PORT filings yet. We sweep new filings monthly.